Online inquiry

IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13814MR)

This product GTTS-WQ13814MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13814MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13891MR IVTScrip™ mRNA-Anti-PDGFRB, REGN-2176(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-2176
GTTS-WQ10279MR IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA LFG 316
GTTS-WQ8401MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA HS006
GTTS-WQ5557MR IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDP-771
GTTS-WQ310MR IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 19D12
GTTS-WQ13156MR IVTScrip™ mRNA-Anti-NGF, PF-04383119(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PF-04383119
GTTS-WQ15977MR IVTScrip™ mRNA-Anti-Felcat IL31, ZTS-00521505(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00521505
GTTS-WQ11980MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA MM-005
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW